Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Exlinkibart by Lyvgen Biopharma for Advanced Malignancy: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase...
Dalnicastobart by Lyvgen Biopharma for Advanced Malignancy: Likelihood of Approval
Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase...
Dalnicastobart by Lyvgen Biopharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...
Dalnicastobart by Lyvgen Biopharma for Hypopharyngeal Cancer: Likelihood of Approval
Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...
Dalnicastobart by Lyvgen Biopharma for Solid Tumor: Likelihood of Approval
Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Dalnicastobart by Lyvgen Biopharma for Head And Neck Carcinoma: Likelihood of Approval
Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Head And Neck Carcinoma. According to...
Pradusinstobart by Lyvgen Biopharma for Solid Tumor: Likelihood of Approval
Pradusinstobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Exlinkibart by Lyvgen Biopharma for Head And Neck Carcinoma: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Head And Neck Carcinoma. According to...
Exlinkibart by Lyvgen Biopharma for Metastatic Uveal Melanoma: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Metastatic Uveal Melanoma. According to GlobalData,...
Exlinkibart by Lyvgen Biopharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
Exlinkibart by Lyvgen Biopharma for Metastatic Ovarian Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...
Exlinkibart by Lyvgen Biopharma for Acral Lentiginous Melanoma: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Acral Lentiginous Melanoma. According to GlobalData,...
Exlinkibart by Lyvgen Biopharma for Oropharyngeal Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Laryngeal Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Hypopharyngeal Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Esophageal Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Solid Tumor: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...
Exlinkibart by Lyvgen Biopharma for Gastric Cancer: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...